A new generation of Genetically Modified (GM) vaccines: How to overcome the hurdles from bench to practice?

Flanders Vaccine’s Symposium: 


A new generation of Genetically Modified (GM) vaccines: How to overcome the hurdles from bench to practice?

March 19, 2019 

FOD-WASO – Ernest Blerotstraat 1, 1070 Brussels
(located on the opposite of Pullman Hotel or exit ‘Hortaplein’ of the railway station Brussels South/Midi)


deadline March 5, 2019

To overcome the limitations of traditional vaccines, the development and use of novel types of vaccines, especially those based on GM technology, are being considered more frequently.

Although GM vaccines are endowed with unique and beneficial qualities, major regulatory -, safety – and other aspects need clarification.

  • What are the Belgian regulatory guidelines for the development of these novel types of vaccines? Is there a difference with other national regulatory frameworks in European countries?
  • What are the challenges encountered in the pre-clinical and clinical field?
  • How can we guarantee the safety and effectiveness of GM vaccines?
  • Is there an environmental risk associated with the use of GM vaccines?

Join this symposium and learn more about these current and interesting topics. A panel of experts will be happy to answer your questions and fuel the discussion.


12:15-13:00: Registration and Welcome lunch

13:00-13:10: Introduction by Prof. Corinne Vandermeulen, KU Leuven

13:10-13:40: Belgian regulatory framework and guidance on the use of genetically modified vaccines in a clinical setting
By Stephanie Mali, Center of Excellence for Vaccines, FAMHP, Katia Pauwels, Biosafety & Biotechnology unit, Sciensano & Florence Kauffmann, Global Medical Affairs manager, GSK

13:40-14:00: European Regulatory aspect of GM Vaccines
by Prof. Dr. Pieter Neels, consultant, IABS

14:00-14:15: Experiences from the  pre-clinical field: yellow fever vaccine-PLLAV technology
by Dr. Kai Dallmeier, Research Expert Virology & Chemotherapy, Group Leader Molecular Vaccinology and Vaccine Discovery, KU Leuven

14:15-14:30: Experiences from the veterinary clinical field
by Dr. Melody Janssen, Virovet

14:30-15:00: COFFEE BREAK

15:00-15:20: Experiences from the clinical field
by Janssen Pharmaceutica

15:20-15:40: Experiences from the clinical field in Belgium
by Bruno Speder, Head Clinical Regulatory Affairs and Consultancy, SGS

15:40-16:20: Interactive Panel Discussion 

16:20-16:30: Closing of the day by Prof Pierre Van Damme, UAntwerpen

16:30-17:30: Networking reception


Interactive Panel Discussion: Questions for the expert panel can be submitted to info@flandersvaccine.be until March 5, 2019. There will also be the possibility to ask your questions on the spot.

For REGISTRATION, click <<here>>

(registration is open until March 5, 2019)

Cancellation Policy:
Notifications received upon 2 weeks before the start of the event, get refunded for 100%. Cancellation requests received less than 2 weeks before the start of the event won’t be refunded. No-shows on the day of the event will not be refunded and are requested to pay the full fee. Replacement by a colleague is always allowed.

This symposium is organised in collaboration with the Federal Agency of Medicines and Health Products (FAMHP).